NASDAQ:OCUL - Ocular Therapeutix Stock Price, Forecast & News

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.01. The biopharmaceutical company earned $0.83 million during the quarter, compared to analysts' expectations of $1.09 million. Ocular Therapeutix had a negative return on equity of 383.58% and a negative net margin of 3,141.58%. View Ocular Therapeutix's Earnings History.

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ocular Therapeutix.

6 Wall Street analysts have issued 1 year target prices for Ocular Therapeutix's stock. Their forecasts range from $3.00 to $24.00. On average, they anticipate Ocular Therapeutix's share price to reach $8.67 in the next twelve months. This suggests a possible upside of 87.2% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix.

News coverage about OCUL stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ocular Therapeutix earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Ocular Therapeutix.

Some companies that are related to Ocular Therapeutix include Achillion Pharmaceuticals (ACHN), Phathom Pharmaceuticals (PHAT), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals (KNSA), ZIOPHARM Oncology (ZIOP), Applied Therapeutics (APLT), Aprea Therapeutics (APRE), Dova Pharmaceuticals (DOVA), Eagle Pharmaceuticals (EGRX), Vanda Pharmaceuticals (VNDA), Provention Bio (PRVB), Collegium Pharmaceutical (COLL), CannTrust (CNTTF), Stoke Therapeutics (STOK) and Homology Medicines (FIXX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Celgene (CELG), Omeros (OMER), Cara Therapeutics (CARA), TG Therapeutics (TGTX), Egalet (EGLT), Melinta Therapeutics (MLNT) and Canopy Growth (CGC).

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OCUL stock can currently be purchased for approximately $4.63.

Ocular Therapeutix has a market capitalization of $222.61 million and generates $1.99 million in revenue each year. The biopharmaceutical company earns $-59,980,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Ocular Therapeutix employs 167 workers across the globe.View Additional Information About Ocular Therapeutix.

The official website for Ocular Therapeutix is http://www.ocutx.com/.

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]